Abstract Background Diseases caused by Streptococcus pneumoniae (S. pneumoniae)
continue to cause substantial morbidity and mortality throughout the world. Polysaccharide …

Background Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia …

Clin Microbiol Infect 2011; 17 (Suppl. 6): E1–E59 Abstract This document is an update of
Guidelines published in 2005 and now includes scientific publications through to May 2010 …

Background: Clinical trials and meta-analyses have produced conflicting results of the
efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to …

Two pneumococcal vaccines currently exist and have been recommended for the prevention
of pneumococcal infection in adults 65 years of age and older: the 23-valent polysaccharide …

Background. The benefits of using the 23-valent pneumococcal polysaccharide vaccine
(PPV23) are controversial. This study assessed clinical effectiveness of PPV23 in preventing …

This review focuses on DNA vaccines, denoting the last two decades since the early
substantiation of preclinical protection was published in Science in 1993 by Ulmer et al. In …

The history of vaccination clearly demonstrates that vaccines have been highly successful in
preventing infectious diseases, reducing significantly the incidence of childhood diseases …

Background. This study assessed antibody levels for 5 years after primary vaccination or
revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23). Methods …

Since the virtual eradication of meningitis due to Haemophilus influenzae type B by
vaccination in the developed world, pneumococcal meningitis has become the leading …